Skip to main content
  1. Right Decisions
  2. GGC - Clinical Guideline Platform
  3. Maternity
  4. Back
  5. Antenatal, general
  6. Antenatal Fetal Monitoring, Inpatients (641)
Announcements and latest updates

Right Decision Service newsletter: September 2024

Welcome to the Right Decision Service (RDS) newsletter for September 2024.

1.Business case for permanent provision of the Right Decision Service from April 2025 onwards

This business case has now been endorsed by the HIS Board and will shortly be submitted to Scottish Government.

2. Management of RDS support tickets

To balance increasing demand with available capacity and financial resource, the RDS team and Tactuum are now working together to  implement closer management of support tickets. As a key part of this, we want to ensure clear, timely and consistent communication with yourselves as requesters.  

Editors will now start seeing new messages come through in response to support ticket requests which reflect this tightening up and improvement of our processes.

Key points to note are:

2.1 Issues confirmed by the RDS and Tactuum teams as meeting the critical/urgent and high priority criteria will continue to be prioritised and dealt with immediately.

Critical/urgent issues are defined as:

  1. The Service as a whole is not operational for multiple users. OR
  2. Multiple core functions of the Service are not operational for multiple users.

Example – RDS website outage.

Please remember to email ann.wales3@nhs.scot and his.decisionsupport@nhs.scot with any critical/urgent issues in addition to raising a support ticket.

High priority issues are defined as:

  1. A single core function of the Service is not operational for multiple users. OR:
  2. Multiple non-core functions of the Service are not operational for multiple users.

Example – Build to app not working.

2.2 Support requests that are outwith the warranty period of 12 weeks since the software was originally developed will not be automatically addressed by Tactuum. The RDS team will consider these requests for costed development work and will obtain estimate of effort and cost from Tactuum for priority issues.

2.3 Support tickets for technical issues that are not classified as bugs will not be automatically addressed by Tactuum. The definition of a bug is ‘a defect in the software that is at variance with documented user requirements.’  Issues that are not bugs will also be considered for costed development work.

The majority of issues currently in support tickets fall into category 2 or 3 above, or both.

2.4 Non-urgent requests that require a deployment (i.e a new release of RDS) will normally be factored into the next scheduled release (currently end of Nov 2024 and end of Feb 2025) unless by special agreement with the RDS team.

Please note that we plan to move in the new year to a new system whereby requests all come to an RDS support portal in the first instance and are triaged from there to Tactuum when appropriate.

We will be organising a webinar in a few weeks’ time to take you through the details of the current support processes and criteria.

3. Next scheduled deployment.

The next scheduled RDS deployment will take place at the end of November 2024.  We are reviewing all outstanding support tickets and feature requests along with estimates of effort and cost to determine which items will be included in this deployment.

We will update you on this in the next newsletter and in the planned webinar about support ticket processes.

4. Contingency arrangements for RDS

Many thanks to those of you who attended our recent webinar on the contingency arrangements being put in place to prevent future RDS outages as far as possible and minimise impact if they do occur.  Please contact ann.wales3@nhs.scot if you would like a copy of the slides from this session.

5. Transfer of CKP pathways to RDS

The NES clinical knowledge pathway (CKP) publisher is now retired and the majority of pathways supported by this tool have been transferred to the RDS. Examples include:

NHS Lothian musculoskeletal pathways

NHS Fife rehabilitation musculoskeletal pathways

NHS Tayside paediatric pathways

6. Other new RDS toolkits

Include:

Focus on frailty (from HIS Frailty improvement programme)

NHS GGC Money advice and support

If you would like to promote one of your new toolkits through this newsletter, please contact ann.wales3@nhs.scot

To go live imminently:

  • Focus on dementia
  • NHS Lothian infectious diseases toolkit
  • Dumfries and Galloway Adult Support and Protection procedures
  • SIGN guideline – Prevention and remission of type 2 diabetes

 

7. Evaluation projects

We have recently analysed the results of a survey of users of the Scottish Palliative Care Guidelines toolkit.  Key findings from 61 respondents include:

  • Most respondents (64%) are frequent users of the toolkit, using it either daily or weekly. A further 25% use it once or twice per month.
  • 5% of respondents use the toolkit to deliver direct patient care and 82% use it for learning
  • Impact on practice and decision-making was rated as very high, with 80% of respondents rating these at a 4-5 on a 5 point scale.
  • Impact on time saving was also high, with 74% of respondents rating it from 3-5.
  • 74% also reported that the toolkit improved their knowledge and skills, rating these at 4-5 on the Likert scale

Key strengths identified included:

  • The information is useful, succinct, and easy to understand (31%).
  • Coverage is comprehensive (15%)
  • All information is readily accessible in one place and users value the offline access via mobile app (15%)
  • Information is reliable, evidence-based and up to date (13%)

Users highlighted key areas for improvement in terms of navigation and search functionality. The survey was very valuable in enabling us to uncover the specific issues affecting the user experience. Many of these can be addressed through content management approaches. The issues identified with search results echo other user feedback, and we are costing improvements with a view to implementation in the next RDS deployment.

8.RDS High risk prescribing (polypharmacy) decision support embedded in Vision and EMIS primary care E H R systems

This decision support software, sponsored by Scottish Government Effective Prescribing and Therapeutics Division,  is now available for all primary care clinicians across NHS Tayside. Board-wide implementation is also planned for NHS Lothian, and NHS GGC, NHS Ayrshire and Arran and NHS Dumfries and Galloway have initial pilots in progress. The University of Dundee has been commissioned to evaluate impact of this decision support software on prescribing practice.

9. Video tutorials for RDS editors

Ten bite-size (5 mins or less) video tutorials for RDS editors are now available in the “Resources for providers of RDS tools” section of the RDS.  These cover core functionality including Save and preview, content page and media management, password management and much more.

10. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Wednesday 23rd October 4-5 pm
  • Tuesday 29th October 11 am -12 pm

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

 

Antenatal Fetal Monitoring, Inpatients (641)

Warning
Please report any inaccuracies or issues with this guideline using our online form

There is a recognised need for fetal monitoring for high risk patients whilst inpatients within the maternity unit. Although there is no clear evidence that antenatal cardiotocography improves perinatal outcome (Grivell et al, 2015) the main purpose of CTG recordings is to identify when there is concern about fetal well-being to enable interventions to be carried out before the fetus is harmed (Beckmann 2014).

The aim of this guideline is to provide a standardised approach to fetal monitoring within the inpatient setting for high risk patients.

All patients greater than 20 weeks gestation should have the fetal heart auscultated each day as a minimum as part of routine maternal observations. Where a patient is admitted to the antenatal ward, the admitting obstetrician must ensure a clear, defined plan stating the type and frequency of fetal monitoring is made and communicated to the midwifery staff.

Indications for antepartum cardiotocography

Some of the most common reasons for admission to the antenatal ward are highlighted below. Any plan for fetal monitoring may be directed by a medical plan of care.

Antepartum cardiotocography (CTG) should be considered in women of 26+0 gestation and above. CTG’s carried out before 28 weeks should be performed and interpreted with caution, the decision to do so must be made on an individual basis by a senior obstetrician. The fetal autonomic nervous system is not mature and therefore the patterns of fetal heart rate which may be expected at later gestations are not present. Also there is increased possibility of signal loss and poor quality CTG at earlier gestations (Afors and Chandraharan, 2011). All CTG traces should be peer reviewed by a trained team member. However, all normal CTG traces on fetuses below 32 weeks gestation should also be peer reviewed by an obstetrician during the shift.

If CTG is of poor quality there should be early recourse to ultrasound location of the fetal heart rate (ideally within 20 minutes).

Abdominal examination

A full abdominal examination should be carried out and documented prior to commencing a CTG trace. Ensure the woman has emptied her bladder and is comfortable. Measure fundal height in centimetres, palpate and document the findings. The fetal heart should be auscultated with a Pinard or doptone prior to commencement (Perinatal Institute 2018).

Cardiotocography interpretation

When reviewing the cardiotocograph (CTG) trace it is important to assess and document any contractions and all four features of fetal heart rate;

  • Baseline rate
  • Baseline variability
  • Presence or absence of decelerations
  • Presence of accelerations

It is also important to record maternal heart rate. Where there is any difficulty in categorising or interpreting a CTG trace, a review by a senior midwife or obstetrician should be obtained.

The RCOG Green-top Guideline on the management of reduced fetal movements recommends that interpretation of the antenatal CTG fetal heart rate pattern can be assisted by adopting the NICE classification of fetal heart rate features as indicated in their intrapartum care guideline. Therefore, as is the case when classifying intrapartum CTGs, it would seem reasonable to use a structured pro forma to ensure the use of consistent terminology. However, using an intrapartum pro forma is not appropriate as it acknowledges that some decelerations are acceptable in labour, which clearly cannot be the case for antenatal CTGs where there are no contractions.

Baseline rate (beats/minute) This is the average fetal heart rate within a ten minute window.

Baseline variability (beats/minute) This refers to the variation of fetal heart rate from one beat to the next. Variability occurs as a result of the interaction between the nervous system, chemoreceptors, baroreceptors and cardiac responsiveness.

Accelerations are an abrupt increase in the baseline fetal heart rate of greater than 15 bpm for greater than 15 seconds. The presence of fetal heart rate accelerations, even with reduced baseline variability, is generally a sign that the baby is healthy.

Decelerations are an abrupt decrease in the baseline fetal heart rate of greater than 15 bpm for greater than 15 seconds.

Any decelerations on an antenatal CTG should be considered abnormal and prompt medical review.

This pro forma has been adapted from PROMPT training and should be utilised for the classification of CTG traces in non-labouring women only.

Antenatal CTGReassuringNon-reassuring
Baseline rate (bpm)110-160 rate:Less than 109
More than 161
Sinusoidal pattern for 10 minutes or more
Variability5 bpm or moreLess than 5 bpm for more than 40 minutes
AccelerationPresentNone for 40 minutes
DecelerationsNoneUnprovoked deceleration/s
Decelerations related to uterine tightening (not in labour)
OpinionNormal CTG (all features reassuring)Abnormal CTG (1 or more non-reassuring features)

Antenatal CTG classification
Normal: A CTG where all four features fall into the ‘reassuring’ category.
Abnormal: A CTG with any non reassuring features (including any decelerations)

When an abnormal CTG is identified, it should be reviewed by an experienced obstetrician as soon as possible (within 30 minutes) to make a clear individualised action plan

Conservative measures

If there are any concerns about the baby’s wellbeing, be aware of the possible underlying causes and start one or more of the following conservative measures based on assessment of the most likely causes: encourage the woman to mobilise or adopt an alternative position ( and to avoid being supine); offer intravenous fluids if the woman is hypotensive or tachycardic.

All cardiotocograph traces must be peer reviewed prior to completion by either a member  of midwifery staff or an obstetrician and documented appropriately. If conservative measures fail to resolve an abnormal CTG trace, immediate review by an obstetrician should be sought and a clear and concise plan documented.

Preterm fetal monitoring

Antepartum cardiotocography should be considered in women of 26+0 weeks gestation and above. Any CTG carried out before 26 weeks should be performed and interpreted with caution. The decision to do so must be based on an individual basis by a consultant obstetrician.

Evidence suggests that the baseline fetal heart rate in preterm fetuses is at the higher end of the normal range for a term fetus for physiological reasons, but that this reverts to the range more consistent with term fetuses as gestation advances. However, any rate more than 160 bpm should be defined as tachycardia across all preterm gestational ages. The baseline variability may be reduced at preterm gestations for physiological reasons. However, at term, fetal heart rate variability is an important clinical indicator of fetal acid base balance and oxygenation of the autonomic nerve centres within the brain (NICE 2015).

Fetal heart rate decelerations are common and normal at very early preterm gestations (26 weeks and less) reflecting immature development of cardioregulatory mechanisms. The presence of shallow or short-lived decelerations in very preterm babies should not be considered necessarily as indicative of hypoxia when all other CTG features are reassuring.

From 32 weeks, baseline fetal heart rate and variability should be similar to that in term fetuses and accelerations with an amplitude of more than 15 beats from the baseline should be present as an indicator of fetal wellbeing. Decelerations can be interpreted as for the term fetus (NICE, 2015).

Antenatal ward fetal monitoring care plans

All care should be provided in conjunction with local guidelines and medical plan

There is little evidence regarding the timing and frequency of antenatal CTG monitoring within an inpatient setting. The following care plan has been devised from best practice within the antenatal ward setting.

A full antenatal examination should be carried out on admission to the ward including blood pressure, heart rate, oxygen saturations, temperature, respiratory rate, urinalysis and abdominal examination and fetal heart rate. A CTG trace should be carried out where indicated.

Antenatal fetal monitoring care plan table

Administration of intra muscular opiate analgesia on the antenatal ward

Opiate analgesia crosses the placenta acting as a vasoconstrictor of the placental vasculature. This may result in reduced fetal tone, reduced fetal movements and reduced- to-absent fetal breathing movements (Kopecky et al, 2000).

Although a CTG may not be indicated in low risk women, in order to ensure fetal wellbeing, CTG monitoring should be commenced prior to administration. On completion on a normal CTG trace, this should be discontinued then the fetal heart should then be auscultated and documented one hour post administration. It is important to remember that a cardiotocograph trace may then show non-reassuring or abnormal baseline variability following the administration of opiate analgesia and should be considered when interpreting the CTG.

Editorial Information

Last reviewed: 18/04/2019

Next review date: 01/04/2024

Author(s): Mandy Reid.

Approved By: Obstetrics Clinical Governance Group

Document Id: 641

References

Afors, K. and Chandraharan, E. (2011) Use of Continuous Electronic Fetal Monitoring in a Preterm Fetus: Clinical Dilemmas and Recommendations for Practice. Journal of Pregnancy Volume 2011, Article ID 848794. Available at https://www.hindawi.com/journals/jp/2011/848794/

Beckmann, M. (2014) National German Guideline: Guideline on the use of CTG During Pregnancy and Labour. Geburtsh Frauenheilk.

Grivell RM, Alfirevic Z, Gyte GML, Devane D. Antenatal cardiotocography for fetal assessment (2015). Cochrane Database of Systematic Reviews, Issue 9. Art. No.: CD007863. DOI: 10.1002/14651858.CD007863.pub4.

Kopecky, E, Ryan, M, Barrett et al (2000) Fetal response to maternally administered morphine. American Journal of Obstetrics and Gynaecology. Vol 183-2, August 2000 Available at https://ac.els-cdn.com/S0002937800746710/1-s2.0S0002937800746710- main.pdf?_tid=77089bd4-3733-4276-9b11- f5216d79c2f0&acdnat=1521122523_2af4473790c63d9f12e65e3d59fd5cbe

National Institute for Health Care and Excellence (2017) Intrapartum Care (NICE Guideline CG190) Available at: https://www.nice.org.uk/guidance/cg190

National Institute for Health Care and Excellence (2015) Preterm Labour and Birth (NICE Guideline 25) Available at: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0080792/pdf/PubMedHealth_PM H00 80792.pdf

Perinatal Institute (2018) Fetal Growth- Fundal Height Measurements. Available online at: https://www.perinatal.org.uk/FetalGrowth/FundalHeight.aspx